Survival of patients with cancer associated thrombosis at the Uganda Cancer Institute.
Uganda
cancer
thrombosis
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
11
2020
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
The occurrence of venous thromboembolism (VTE) in patients with cancer leads to a reduced life expectancy. There is an increased incidence of cancer and its associated mortality in Uganda. We described the survival and characteristics of patients with cancer associated thrombosis (CAT) in a tertiary oncology centre in Uganda. We performed a retrospective study on patients with CAT at the Uganda Cancer Institute (UCI) using a homogenous purposive sampling method. One hundred and eleven patients with documented VTE were included in the analysis. At entry, the mean age was 52.4 years, and 69 were female. Ninety eight had deep venous thrombosis, while 12 had pulmonary embolism. The most common cancer diagnoses were haematologic (30), gynaecologic (20) and prostate (17) cancers. Treatment regimens included anticoagulation with low-molecular weight heparin (LMWH) (72) and combined LMWH with warfarin (22). The median overall survival (OS) was 6.3 months, with a 1-year survival rate of 41.5%. Patients with significantly increased hazard of mortality were those with upper gastrointestinal (UGI) malignancies, colorectal and breast cancers. Patients with a body mass index of 25-29.9 kg/m The OS of patients with CAT at the UCI is short. Most patients with CAT presented with advanced stage cancers and at a relatively young age. Patients with UGI, colorectal and breast cancers had increased hazards of mortality, whereas those who were overweight had a slight reduction in the hazard of mortality.
Sections du résumé
BACKGROUND
BACKGROUND
The occurrence of venous thromboembolism (VTE) in patients with cancer leads to a reduced life expectancy. There is an increased incidence of cancer and its associated mortality in Uganda. We described the survival and characteristics of patients with cancer associated thrombosis (CAT) in a tertiary oncology centre in Uganda.
METHODS
METHODS
We performed a retrospective study on patients with CAT at the Uganda Cancer Institute (UCI) using a homogenous purposive sampling method.
RESULTS
RESULTS
One hundred and eleven patients with documented VTE were included in the analysis. At entry, the mean age was 52.4 years, and 69 were female. Ninety eight had deep venous thrombosis, while 12 had pulmonary embolism. The most common cancer diagnoses were haematologic (30), gynaecologic (20) and prostate (17) cancers. Treatment regimens included anticoagulation with low-molecular weight heparin (LMWH) (72) and combined LMWH with warfarin (22). The median overall survival (OS) was 6.3 months, with a 1-year survival rate of 41.5%. Patients with significantly increased hazard of mortality were those with upper gastrointestinal (UGI) malignancies, colorectal and breast cancers. Patients with a body mass index of 25-29.9 kg/m
CONCLUSION
CONCLUSIONS
The OS of patients with CAT at the UCI is short. Most patients with CAT presented with advanced stage cancers and at a relatively young age. Patients with UGI, colorectal and breast cancers had increased hazards of mortality, whereas those who were overweight had a slight reduction in the hazard of mortality.
Identifiants
pubmed: 33912237
doi: 10.3332/ecancer.2021.1212
pii: can-15-1212
pmc: PMC8057783
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1212Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
All the authors have declared no conflicts of interest.
Références
Intern Med J. 2012 Jan;42(1):71-4
pubmed: 21118408
Infect Agent Cancer. 2019 Sep 10;14:24
pubmed: 31516547
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):196-205
pubmed: 27913480
N Engl J Med. 2000 Dec 21;343(25):1846-50
pubmed: 11117976
J Clin Oncol. 2006 Mar 1;24(7):1112-8
pubmed: 16505431
Arch Intern Med. 2006 Feb 27;166(4):458-64
pubmed: 16505267
Afr J Med Med Sci. 2013 Jun;42(2):177-81
pubmed: 24377204
Thromb Res. 2015 Sep;136(3):535-41
pubmed: 26168693
Cancers (Basel). 2018 Oct 11;10(10):
pubmed: 30314362
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Eur Respir Rev. 2019 Mar 27;28(151):
pubmed: 30918022
Int J Cancer. 2014 Jul 15;135(2):432-9
pubmed: 24615279
Blood Adv. 2018 Nov 27;2(22):3226-3256
pubmed: 30482764
Cancer Manag Res. 2013 Jul 26;5:165-78
pubmed: 23926439
Eur J Cancer. 2009 Jan;45(1):65-73
pubmed: 19068274
Br J Cancer. 2010 Sep 28;103(7):947-53
pubmed: 20842120
Thromb Haemost. 2010 Feb;103(2):338-43
pubmed: 20024496
Medicine (Baltimore). 1999 Sep;78(5):285-91
pubmed: 10499070
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620954282
pubmed: 32877229
Cancer. 2007 May 15;109(10):1989-95
pubmed: 17397035
Oncologist. 2021 Jan;26(1):e24-e40
pubmed: 33275332
JAMA Oncol. 2016 Sep 1;2(9):1137-45
pubmed: 27196302
Dis Esophagus. 2008;21(7):575-81
pubmed: 18459989
Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1468-73
pubmed: 17627012
Gastric Cancer. 2018 Nov;21(6):913-924
pubmed: 29651648